Inhibitors of human mast cell serine proteases and potential therapeutic applications

Bibliography

• WELLE M: Development, significance, and heteroge- neity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J. Leukocyte Biol. (1997) 61(3):233–245.
   Google Scholar
• ••A review article that provides a condensed overview of MCbiology with an emphasis on phenotype heterogeneity.
   Google Scholar
• YONG L: The mast cell: origin, morphology, distribu- tion, and function. Exp. ToxicoL PathoL (1997) 49(6)409–424.
   Google Scholar
• ••A review article that provides a comprehensive overview ofthe MC and a historical perspective without attention to MC proteases.
   Google Scholar
• ARTUC M, HERMES B, STECKELINGS UM, GRUTZKAU A, HENZ BM: Mast cells and their mediators in cutaneous wound healing - active participants or innocent bystanders? Exp. Dermatol. (1999) 8(0:1–16.
   Google Scholar
• JACOBI HH, HANG Y, TINGSGAARD PK et al: Dendritic mast cells in the human nasal mucosa. Lab. Invest. (1998) 78(9):1179–1184.
   Google Scholar
• REN S, SAKAI K, SCHWARTZ LB: Regulation of human mast cell p-tryptase: conversion of inactive monomer to active tetramer at acidic pH. J. Immunol. (1998) 160(9)4561–4569.
   Google Scholar
• •A research article that examines the kinetics of tryptase tetramer-monomer interconversion as a function of pH and heparin concentration. The authors suggest that reactivation of the tryptase monomer might be relevant in vivo after recruitment to an acidic or heparin rich site.
   Google Scholar
• HSIEH K: Localization of an effective fibrin 0-chain polymerization site: implications for the polymeriza-tion mechanism. Biochemist-1y (1997) 36:9381–9387.
   Google Scholar
• THOMAS VA, WHEELESS CJ, STACK MS, JOHNSON DA: Human mast cell tryptase fibrinogenolysis: kinetics, anticoagulation mechanism, and cell adhesion disrup-tion. Biochemistry (1998) 37 8) 2291–2298.
   PubMedGoogle Scholar
• •A research article that reports on mechanistic studies related to tryptase induced fibrinogenolysis and implications for tryptase as an anticoagulant and modulator of cellular interactions.
   Google Scholar
• CHAN H, ELROD KC, NUMEROF RP, SIDERIS S, CLARK JM: Expression and characterization of recombinant mast cell tryptase. Protein Expression Puri (1999) 15 3) :251–257.
   Google Scholar
• MCGRATH ME, OSAWA AE, BARNES MG, CLARK JM, MORTARA KD, SCHMIDT BF: Production of crystalliz-able human chymase from a Bacillus subtilis system. FEBS Lett. (1997) 413(3):486–488.
   PubMedGoogle Scholar
• HUANG C, SALI A, STEVENS RL: Regulation and function of mast cell proteases in inflammation. J. Clin. Immunol. (1998) 18(3):169–183.
   PubMedGoogle Scholar
• •A review article that focuses on recent findings related to the regulated expression of MC proteases and relevant advances in protease expression.
   Google Scholar
• HARVIMA RJ, HARVIMA IT, DULL D, DUNDER UK, SCHWARTZ LB: Identification and characterization of multiple forms of tryptase from human mast cells. Arch. Dermatol. Res. (1999) 291(2/3)73–80.
   Google Scholar
• STACK MS, JOHNSON DA: Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J. Biol. Chem. (1994) 269(13)9416–9419.
   Google Scholar
• LOHI J, HARVIMA I, KESKI-OJA J: Pericellular substratesof human mast cell tryptase: 72,000 dalton gelatinase and fibronectin. J. Cell. Biochem. (1992) 50(4)337–349.
   Google Scholar
• KIELTY CM, LEES M, SHUTTLEWORTH CA, WOOLLEY D:Catabolism of intact Type VI collagen microfibrils: susceptibility to degradation by serine proteinases. Biochem. Biophys. Res. Commun. (1993) 191 3) :1230–1236.
   PubMed Web of Science ®Google Scholar
• BROOKS P, CLARK R, CHERESH D: Requirement of vascular integrin avp3 for angiogenesis. Science (1994) 264:569–571.
   PubMed Web of Science ®Google Scholar
• BLAIR RJ, MENG H, MARCHESE MJ et al.: Human mast cells stimulate vascular tube formation: tryptase is a novel, potent angiogenic factor. J. Clin. Invest. (1997) 99(102691–2700.
   Google Scholar
• •A research article that reports on the ability of tryptase to stimulate capillary tube formation in MC and endothelial cell co-cultures. The authors note that treatment with tryptase inhibitors attenuated angiogenic activity.
   Google Scholar
• ARNAOUT R, REN S, SCHWARTZ L: Mast cell tryptase is a mitogen for cultured human endothelial cells. J. Allergy Clin. Immunol. (1998) 101 (Suppl.) :110–111.
   Google Scholar
• KENNEDY J, WRIGHT C: Effect of mast cell tryptase on bronchial smooth muscle cell proliferation. FASEB J. (1998) 12:A175.
   Google Scholar
• AKERS I, LAURENT G, SANJAR S, MCANULTY R: Human lung fibroblasts express protease activated receptor-2 (PAR-2) which mediate the mitogenic effects of mast cell tryptase. FASEB J (1998) 12:A434.
   Google Scholar
• WRIGHT C, KENNEDY J: Promotion of mast cell activa-tion by tryptase. FASEB J (1998) 12:A894.
   Google Scholar
• HE S, WALLS AF: Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. Eur. Pharmacol. (1997) 328(0:89–97.
   PubMed Web of Science ®Google Scholar
• HE S, GACA MDA, WALLS AF: A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase. J. Pharmacol. Exp. Ther. (1998) 286(1):289–297.
   Google Scholar
• •A research article that reports on the ability of tryptase to induce histamine release from MCs in vitro. The authors note that histamine release could be attenuated by treatment with APC366 and suggest a therapeutic role for tryptase inhibitors as MC stabilisers that block amplification of the inflammatory response.
   Google Scholar
• SELWOOD T, MCCASLIN DR, SCHECHTER NM: Sponta-neous inactivation of human tryptase involves confor-mational changes consistent with conversion of the active site to a zymogen-like structure. Biochemistry (1998) 37(38):13174–13183.
   Google Scholar
• ELROD K, MOORE W, ABRAHAM W, TANAKA R: Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep. Am. J. Respir. Crit. Care Med. (1997) 156:375–381.
   PubMed Web of Science ®Google Scholar
• CREGAR L, ELROD KC, PUTNAM D, MOORE WR: Neutro-phil myeloperoxidase is a potent and selective inhibitor of mast cell tryptase. Arch. Biochem. Biophys. (1999) 366(1):125–130.
   PubMed Web of Science ®Google Scholar
• ZHANG MQ, TIMMERMAN H: Mast cell tryptase and asthma. Mediators Inflamm. (1997) 6(5/6.) :311–317.
   Google Scholar
• •A condensed review article that broadly covers the biochemistry of tryptase, implications for tryptase activity in asthma pathology and early small molecule inhibitors of tryptase.
   Google Scholar
• ROSSI G, OLIVIERI D: Does the mast cell still have a key role in asthma? Chest (1997) 112:523–529.
   PubMed Web of Science ®Google Scholar
• ELROD KC, NUMEROF RP: Emerging therapeutic targets in asthma: the rationale for mast cell tryptase inhibi-tion. Emerg. Ther. Targets (1999) 3(2):203–212.
   Google Scholar
• WALLS AF: Mast cell proteases in asthma. Lung Biol. Health Dis. (1998) 117 (Inflammatory Mechanisms in Asthma) :89–110.
   Google Scholar
• KOZIK A, MOORE RB, POTEMPA J, IMAMURA T, RAPALA-KOZIK M, TRAVIS J: A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. J. Biol. Chem. (1998) 273(50)33224–33229.
   Google Scholar
• •A research article that reports on a novel mechanism for bradykinin generation that involves co-processing of oxidised kininogen by both neutrophil elastase and tryptase. The authors suggest that such a kininogenolysis pathway may represent an underlying inflammatory mechanism in vivo.
   Google Scholar
• TAM E, CAUGHEY G: Degradation of airway neuropep-tides by human lung tryptase. Am. J. Respir. Cell Mol. Biol. (1990) 3:27–32.
   PubMed Web of Science ®Google Scholar
• WALLS A, BRAIN S, DESAI A et al.: Human mast celltryptase attenuates the vasodilatory activity of calcitonin gene-related peptide. Biochem. Pharmacol. (1992) 43:1243–1248.
   PubMed Web of Science ®Google Scholar
• MOLINO M, BARNATHAN ES, NUMEROF R et al.: Interac-tions of mast cell tryptase with thrombin receptors and PAR-2. J. Biol. Chem. (1997) 272(7):4043–4049.
   PubMed Web of Science ®Google Scholar
• FOX MT, HARRIOTT P, WALKER B, STONE SR: Identifica-tion of potential activators of proteinase-activated receptor-2. FEBS Lett. (1997) 417(3)267–269.
   Google Scholar
• DERY O, BUNNETT NW: Proteinase-activated receptors: a growing family of heptahelical receptors for thrombin, trypsin and tryptase. Biochem. Soc. Trans. (1999) 27(2):246–254.
   Google Scholar
• •A review article that provides a complete overview of the PAR receptor family. The article covers mechanisms of PAR activation, transmembrane signalling and biological functions with some emphasis on the PAR-2 receptor.
   Google Scholar
• MIRZA H, SCHMIDT VA, DERIAN CK, JESTY J, BAHOU WF:Mitogenic responses mediated through the proteinase-activated receptor-2 are induced by expressed forms of mast cell a- or p-tryptases. Blood (1997) 90(103914–3922.
   Google Scholar
• COMPTON S, CAIRNS J, HOLGATE S, WALLS A: Interac-tion of human mast cell tryptase with endothelial cells to stimulate inflammatory cell recruitment. Int. Arch. Allergy Immunol (1999) 118:204–205.
   Google Scholar
• COMPTON SJ, CAIRNS JA, HOLGATE ST, WALLS AF: Therole of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for 11-16 and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. J. Immunol. (1998) 161 4): 1939–1946.
   PubMed Web of Science ®Google Scholar
• •A research article that reports on the ability of tryptase to function as a pro-inflammatory mediator through endothe-lial cell activation. The authors suggest that activation might be PAR-2 mediated and could represent a critical pathway for leukocyte recruitment to inflammation sites.
   Google Scholar
• WARNER J, SHUTE J, LACKIE P, JULIUS P, LUTTMANN W,KROEGEL C: A possible role for eosinophils and neutrophils in airway remodelling in asthma. J. Allergy Clin. Immunol. (1998) 99 (Suppl.):371.
   Google Scholar
• HE S, PENG Q, WALLS AF: Potent induction of a neutro-phil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosino-phil recruitment by histamine. J. Immunol. (1997) 159(12)6216–6225.
   Google Scholar
• BARRIOS VE, MIDDLETON SC, KASHEM MA, HAVILL AM,TOOMBS CF, WRIGHT CD: Tryptase mediates hyperre-sponsiveness in isolated guinea pig bronchi. Life Sci. (1998) 63(26)2295–2303.
   Google Scholar
• JOHNSON PRA, AMMIT AJ, CARLIN SM, ARMOUR CL, CAUGHEY GH, BLACK JL: Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus. Eur. Respir. J. (1997) 10(0:38–43.
   Google Scholar
• CLARK J, ABRAHAM W, FISHMAN C et al.: Tryptaseinhibitors block allergen-induced airway and inflam-matory responses in allergic sheep. Am. J. Respir. Grit. Care Med. (1995) 152:2076–2083.
   PubMed Web of Science ®Google Scholar
• KRISHNA M, CHAUHAN A, LITTLE L et al.: Effect ofinhaled APC-366 on allergen-induced bronchocon-striction and airway hyperresponsiveness to histamine in atopic asthmatics. Am. J. Respir. Crit. Care Med. (1998) 157:A456.
   Google Scholar
• SEPPER R, KONTTINEN YT, KEMPPINEN P, SORSA T, EKLUND KK: Mast cells in bronchiectasis. Ann. Med. (Helsinki) (1998) 30(3): 307–315.
   PubMed Web of Science ®Google Scholar
• SEPPER R, KONTTINEN Y, KEMPPINEN P, SORSA T,EKLUND K: Potentiative effects of neutral proteinases in an inflamed lung: relationship of neutrophil procollagenase (proMMP-8) to plasmin, cathepsin G and tryptase in brochietasis in vivo. Eur. Respir. J. (1998) 10:2788–2793.
   Google Scholar
• •A research article that implicates tryptase and possibly cathepsin G in the activation of MMP activity in vivo supported by immunological studies involving patients with BE. Importantly, the authors note that the plasmin-plasminogen activator cascade was down regulated.
   Google Scholar
• GRUBER B, SCHWARTZ L, RAMAMURTHY N, IRANI A, MARCHESE M: Activation of latent rheumatoid synovial collagenase by human mast cell tryptase. J. Immunol (1988) 140:3936–3942.
   PubMed Web of Science ®Google Scholar
• GRUBER B, MARCHESE M, SUZUKI K et al.: Synovialprocollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activa-tion. J. Clin. Invest. (1989) 84:1657–1662.
   PubMed Web of Science ®Google Scholar
• COUSSENS LM, RAYMOND WW, BERGERS G et al.: Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. (1999) 13(10:1382–1397.
   PubMed Web of Science ®Google Scholar
• CAIRNS JA, WALLS AF: Mast cell tryptase stimulates the synthesis of Type I collagen in human lung fibroblasts. Clin. Invest. (1997) 99 6) :1313–1321.
   Google Scholar
• •A research article that reports on the ability of tryptase to stimulate fibroblasts and ECM production. The article provides some overview discussion on fibrotic disease and the authors suggest a possible therapeutic role for tryptase inhibitors in the treatment of chronic conditions associated with MC activity.
   Google Scholar
• GRUBER BL, KEW RR, JELASKA A et al.: Human mast cells activate fibroblasts. Tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J. Immunol (1997) 158(5) :2310–2317.
   Google Scholar
• •A research article that similarly reports on the ability of tryptase to stimulate fibroblasts and also provides evidence for the induction of fibroblast chemotaxis.
   Google Scholar
• SCHECHTER NM, BRASS LF, LAVKER RM, IENSEN PJ: Reaction of mast cell proteases tryptase and chymase with protease activated receptors (PARs) on keratino-cytes and fibroblasts. J. Cell. Physiol. (1998) 176(2):365–373.
   PubMed Web of Science ®Google Scholar
• WELKER P, GRABBE J, GRUTZKAU A, HENZ BM: Effects of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature human mast cells (HMC-1). Immunology (1998) 94(3):310–317.
   Google Scholar
• •A research article that focuses on the effect of specific fibroblast derived cytokines on MC maturation. The work provides some new insight into the complex network that modulates MC phenotype differentiation and function.
   Google Scholar
• WALLS A, BENNETT A, GODFREY R, HOLGATE S: Mastcell tryptase and histamine concentrations in bronchoalveolar lavage fluid from patients with interstitial lung disease. Clin. Sci. (London) (1991) 81:183–188.
   Google Scholar
• KAWANAMI O, FERRANS V, FULMER J, CRYSTAL R: Ultrastructure of pulmonary mast cells in patients with fibrotic lung disease. Lab. Invest. (1979) 40:717–734.
   Google Scholar
• AKIMOTO S, ISHIKAWA O, IGARASHI Y, KUROSAWA M,MIYACHI Y: Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br. J. Dermatol (1998) 138:399–406.
   PubMed Web of Science ®Google Scholar
• YAMASHIRO M, KOUDA W, KONO N, TSUNEYAMA K,MATSUI O, NAKANUMA Y: Distribution of intrahepatic mast cells in various hepatobillary disorders. Virchows Arch. (1998) 433:471–479.
   Google Scholar
• •A research article that summarises recent immunological studies in diseased liver tissue. The authors suggest that MC activity may play a role in the pathology of certain biliary diseases where fibrosis is involved.
   Google Scholar
• AKIYOSHI H, TERADA T: Mast cell, myofibroblast and nerve terminal complexes in carbon tetrachloride-induced cirrhotic rat livers. J. Hepatol (1998) 29:112–119.
   PubMed Web of Science ®Google Scholar
• HAAK-FRENDSCHO M, OKRAGLY A, NILES A et al.: Elevated NT-3, NGF, GDNF and tryptase levels in the urine of bladder cancer and interstitial cystitis patients. FASEB J (1998) 12:A596.
   Google Scholar
• MATSUZAKI S, CANIS M, DARCHA C, FUKAYA T, YAJIMAA, BRUHAT M: Increased mast cell density in peritoneal endometriosis compared with eutopic endometrium with endometriosis. Am. J. Repro. Immunol. (1998) 40:291–294.
   PubMed Web of Science ®Google Scholar
• GRANDALIANO G, MONNO R, RANIERI E, VALENTE M, GESUALDO L, SCHENA F: Glomerular tryptase and proteinase-activated receptor-2 (PAR-2) expression in IgA nephropathy (IgAN): a potential role in the pathogenesis of progressive glomerular damage. J. Am. Soc. Nephrol. (1998) 9:495A.
   Google Scholar
• LIANG Y, MARCUSSON J, JACOBI H, HAAK-FRENDSCHO M, JOHANSSON 0: Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. J. Cutan. Pathol. (1998) 25:189–198.
   Google Scholar
• STEINHOFF M, THOMA M, CORVERA C et al.: Protease-activated receptor-2 (PAR-2) in human skin: mast cell tryptase activates keratinocytes and endothelial cells through PAR-2. J. Dermatol. Sci. (1998) 16:S74.
   Google Scholar
• NAUKKARINEN A, HARVIMA I, PAUKKONEN K, AALTOM-L, HORSMANHEIMO M: Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch. Dermatol. Res. (1993) 285:341.
   Google Scholar
• MICHAELSSON G, KRAAZ W, HAGFORSEN E, PIHL-LUNDIN I, LOOF L: Psoriasis patients have highly increased numbers of tryptase-positive mast cells in the duodenal stroma. Br. J. Dermatol. (1997) 136:866–870.
   PubMed Web of Science ®Google Scholar
• HARVIMA I, HAAPANEN L, ACKERMANN L, NAUKKARI-NEN A, HARVIMA R, HORSMANHEIMO M: Decreased chymase activity is associated with increased levels of protease inhibitors in mast cells of psoriatic lesions. Acta Derm. Venereol. (1999) 79(2):98–104.
   PubMed Web of Science ®Google Scholar
• ARVIKALLIO A, NAUKKARINEN A, HERVIMA I, AALTO M, HORSMANHEIMO M: Quantitative analysis of tryptase-and chymase- containing mast cells in atopic dermatitis and nummular eczema. Br. J. Dermatol (1997) 136:871–877.
   Google Scholar
• COOPER K: Atopic dermatitis: recent trends in pathogensis and therapy. J. Invest. Dermatol. (1994) 102:128–137.
   PubMed Web of Science ®Google Scholar
• DI LORENZO G, MANSUETO P, MELLUSO Metal: Allergicrhinitis to grass pollen: measurement of inflammatory mediators of mast cell and eosinophils in native nasal fluid lavage and in serum out of and during pollen season. J. Allergy Clin. Immunol. (1997) 100:832–836.
   PubMed Web of Science ®Google Scholar
• WILSON SJ, LAU L, HOWARTH PH: Inflammatory mediators in naturally occurring rhinitis. Clin. Exp. Allergy (1998) 28(2):220–227.
   PubMed Web of Science ®Google Scholar
• •A research article that summarises immunological studies involving patients with seasonal and allergic rhinitis. The study provides compelling evidence of MC involvement in rhinitis.
   Google Scholar
• MOTOJIMA S, FRIGAS E, LOEGERING D, GLEICH G:Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am. Rev. Respir. Dis. (1989) 139:801–805.
   PubMed Web of Science ®Google Scholar
• BISCHOFF S, WEDEMEYER J, HERRMANN A: Quantitativeassessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology (1996) 28: 1–13.
   PubMed Web of Science ®Google Scholar
• SCHWAB D, RAITHEL M, HAHN EG: Evidence for mastcell activation in collagenous colitis. Inflamm. Res. (1998) 47 (Suppl. 1):S64–S65.
   Google Scholar
• RAITHEL M, PACURAR A, WINTERKAMP S, ULRICH P, HOCHBERGER J, HAHN E: Mast cell tryptase enables the identification of patients with manifest gastrointes-tinal allergy and correlates with disease activity. Gastroenterology (1997) 112:A395.
   Google Scholar
• WINTERKAMP S, RAITHEL M, WEIDENHILLER M, SCHWABD, HOCHBERGER J, HAHN E: Local distribution of mast cell tryptase in the lower gastrointestinal tract in Crohn's disease. Gastroenterology (1998) 114:A1114–A1115.
   Google Scholar
• RAITHEL M, WINTERKAMP S, PACURAR A, ULRICH P, HOCHBERGER J, HAHN E: Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Gastroenterology (1998) 114:A408.
   Google Scholar
• SANTOS J, SAPERAS E, NOGUEIRAS C et al: Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology (1998) 114:640–648.
   PubMed Web of Science ®Google Scholar
• JEZIORSKA M, MCCOLLUM C, WOOLLEY DE: Mast cell distribution, activation, and phenotype in atheroscle-rotic lesions of human carotid arteries. J. Pathol. (1997) 182(0:115–122.
   Google Scholar
• JOHNSON JL, JACKSON CL, ANGELINI GD, GEORGE SJ: Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterio-scler., Thromb., Vasc. Biol. (1998) 18(1 0 :1707–1715.
   Google Scholar
• •A research article that provides evidence for tryptase and chymase mediated MMP activation and atherosclerotic plaque destabilisation in vitro. A brief overview of athero-sclerosis is also provided.
   Google Scholar
• PEREIRA PJB, BERGNER A, MACEDO-RIBEIRO S et al: Human 13-tryptase is a ring-like tetramer with active sites facing a central pore. Nature (London) (1998) 392(6673)306–311.
   Google Scholar
• ••A research article that summarises the first crystal structureof active human tryptase tetramer. The authors provide a detailed discussion of the structure and some implications for tryptase inhibitor design.
   Google Scholar
• DI MARCO S, PRIESTLE JP: Structure of the complex of leech-derived tryptase inhibitor (LDTO with trypsin and modeling of the LDTI-tryptase system. Structure (London) (1997) 5(10:1465–1474.
   Google Scholar
• RICE KD, TANAKA RD, KATZ BA, NUMEROF RP, MOORE WR: Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr. Pharm. Des. (1998) 4 5):381–396.
   PubMed Web of Science ®Google Scholar
• •A review article that provides a comprehensive summary of tryptase biology as well as a discussion on some first genera-tion dibasic tryptase inhibitors.
   Google Scholar
• BURGESS LE, NEWHOUSE BJ, IBRAHIM P et al.: Potent selective nonpeptidic inhibitors of human lung tryptase. Proc. Natl. Acad. Sci. USA (1999) 96(15)8348–8352.
   Google Scholar
• ••A research article that provides a detailed SAR as a functionof extended scaffold length in a series of dibasic tryptase inhibitors.
   Google Scholar
• KATZ BA, CLARK JM, FINER-MOORE JS et al.: Design of potent selective zinc-mediated serine protease inhibi-tors. Nature (London) (1998) 391(6667):608–612.
   PubMed Web of Science ®Google Scholar
• ••A detailed research article that provides a discussion oncrystallographic structures of the protease-zinc-ligand complexes, thermodynamics of complex formation as well as some first generation structure-activity relationships.
   Google Scholar
• COMBRINK KD, GUELGEZE HB, MEANWELL NA et al.: 1,2-Benzisothiazol-3-one-1,1-dioxide inhibitors of human mast cell tryptase. J. Med. Chem. (1998) 41(24)4854–4860.
   Google Scholar
• SCHWARTZ LB, IRANI AMA, ROLLER K, CASTELLS MC, SCHECHTER NM: Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. Immunol (1987) 138(8):2611–2615.
   Google Scholar
• MCEUEN AR, SHARMA B, WALLS AF: Regulation of theactivity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. Biochim. Biophys. Acta (1995) 1267(2/3):115–121.
   Google Scholar
• SCHECHTER NM, JORDAN LM, JAMES AM, COOPERMAN BS, WANG ZM, RUBIN H: Reaction of human chymase with reactive site variants of al-antichymotrypsin. Modulation of inhibitor versus substrate properties. J. Biol. Chem. (1993) 268(30:23626–23633.
   Google Scholar
• TAIPALE J, LOHI J, SAARINEN J, KOVANEN PT, KESKI-OJA J: Human mast cell chymase and leukocyte elastase release latent transforming growth factor-131 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem. (1995) 270(9):4689–4696.
   PubMed Web of Science ®Google Scholar
• MIZUTANI H, SCHECHTER N, LAZARUS G, BLACK RA, KUPPER TS: Rapid and specific conversion of precursor interleukin 113 (IL-113) to an active IL-1 species by human mast cell chymase. J. Exp. Med. (1991) 174(0821–825.
   PubMed Web of Science ®Google Scholar
• LONGLEY BJ, TYRRELL L, MA Y et al.: Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc. Natl. Acad. Sci. USA (1997) 94(17):9017–9021.
   PubMed Web of Science ®Google Scholar
• WYPIJ DM, NICHOLS JS, NOVAK PJ, STACY DL, BERMAN J, WISEMAN JS: Role of mast cell chymase in the extracel-lular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem. Pharmacol. (1992) 43 4):845–853.
   PubMed Web of Science ®Google Scholar
• SAARINEN J, KALKKINEN N, WELGUS HG, KOVANEN PT: Activation of human interstitial procollagenase through direct cleavage of the Leu83-Thr84 bond by mast cell chymase. J. Biol. Chem. (1994) 269(27):18134–18140.
   PubMed Web of Science ®Google Scholar
• SUZUKI K, LEES M, NEWLANDS GFJ, NAGASE H, WOOLLEY DE: Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem. J. (1995) 305(1)301–306.
   Google Scholar
• LEES M, TAYLOR DJ, WOOLLEY DE: Mast cell proteinasesactivate precursor forms of collagenase and strome-lysin, but not for gelatinases A and B. Eur. J. Biochem. (1994) 223 1) :171–177.
   PubMedGoogle Scholar
• FANG KC, RAYMOND WW, LAZARUS SC, CAUGHEY GH: Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase. j Clin. Invest. (1996) 97(7):1589–1597.
   PubMed Web of Science ®Google Scholar
• CAUGHEY GH, LEIDIG F, VIRO NF, NADEL JA: Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J. Pharmacol. Exp. Ther. (1988) 244(0:133–137.
   PubMed Web of Science ®Google Scholar
• STEVENS R, FRIEND D, MCNEIL H, SCHILLER V, GHILDYAL N, AUSTEN K: Strain-specific and tissue-specific expression of mouse mast cell secretory granule proteases. Proc. Natl. Acad. Sci. USA (1994) 91(0:128–132.
   PubMed Web of Science ®Google Scholar
• LIAO Y, HUSAIN A: The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can. J. Cardiol. (1995) 11 (Suppl. F):13F–19F.
   Google Scholar
• HUSAIN A: The chymase-angiotensin system in humans. J. Hypertens. (1993) 11(10:1155–1159.
   PubMed Web of Science ®Google Scholar
• WET C-C, MENG QC, PALMER R et al: Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation (1999) 99(19)2583–2589.
   Google Scholar
• WALDECK K, LINDBERG BF, PERSSON K, ANDERSSON K-E: Characterization of angiotensin II formation in human isolated bladder by selective inhibitors of ACE and human chymase: a functional and biochemical study. Br. J. Pharmacol. (1997) 121 6) :1081–1086.
   Google Scholar
• OKUNISHI H: Angiotensin II formation by chymase in the cardiovascular tissue. Nippon Yakurigaku Zasshi (1998) 112(3):203–212.
   Google Scholar
• OKUNISHI H, OKAY, SHIOTA N, KAWAMOTO T, SONG K, MIYAZAKI M: Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn. J. Pharmacol. (1993) 62(2)207–210.
   Google Scholar
• Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percuta-neous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group [comment]. Circulation (1992) 86 1):100–110.
   Google Scholar
• RUBINSTEIN I, NADEL JA, GRAF PD, CAUGHEY GH: Mast cell chymase potentiates histamine-induced wheal formation in the skin of ragweed-allergic dogs. J. UM. Invest. (1990) 86(2):555–559.
   Google Scholar
• HE S, WALLS AF: Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo. Br. J. Pharmacol. (1998) 125(7):1491–1500.
   Web of Science ®Google Scholar
• NUMEROF RP, LEUNG L, SIMPSON PJ: (Submitted).
   Google Scholar
• FUKAMI H, OKUNISHI H, MIYAZAKI M: Chymase: its pathophysiological roles and inhibitors. Curr. Pharm. Des. (1998) 4(6):439–453.
   PubMed Web of Science ®Google Scholar
• ••A recent review on chymase inhibitors and their potentialtherapeutic applications.
   Google Scholar
• EDA M, ASHIMORI A, AKAHOSHI F et al: Peptidyl human heart chymase inhibitors. 1. Synthesis and inhibitory activity of difluoromethylene ketone derivatives bearing P' binding subsites. Bioorg. Med. Chem. Lett. (1998) 8(8):913–918.
   Google Scholar
• EDA M, ASHIMORI A, AKAHOSHI F et al: Peptidyl human heart chymase inhibitors. 2. Discovery of highly selective difluoromethylene ketone derivatives with Glu at P3 site. Bioorg. Merl. Chem. Lett. (1998) 8(8)919–924.
   Google Scholar
• NIWATA S, FUKAMI H, SUMIDA M et al.: Substituted 3- (phenylsulfony1)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase. j Med. Chem. (1997) 40(14):2156–2163.
   PubMed Web of Science ®Google Scholar
• MCGRATH ME, MIRZADEGAN T, SCHMIDT BF: Crystal structure of phenylmethanesulfonyl fluoride-treated human chymase at 1.9 A. Biochemistry (1997) 36(47):14318–14324.
   Google Scholar
• ••A research article describing the key structural features ofrecombinant chymase with a sulphonate ester inhibitor bound in the active site.
   Google Scholar
• PEREIRA PJB, WANG Z-M, RUBIN H et al.: The 2.2 A crystal structure of human chymase in complex with succinyl-Ala-Ala-Pro-Phe-chloromethylketone: structural explanation for its dipeptidyl carboxypepti-dase specificity. J. Mol. Biol. (1999) 286(0:163–173.
   Google Scholar
• ••Another research article describing the key structuralfeatures of recombinant chymase with a peptidyl inhibitor bound in the active site.
   Google Scholar
• SANKER S, CHANDRASEKHARAN UM, WILK D, GLYNIAS MJ, KARNIK SS, HUSAIN A: Distinct multisite synergistic interactions determine substrate specificities of human chymase and rat chymase-1 for angiotensin II formation and degradation. J. Biol. Chem. (1997) 272(5)2963–2968.
   Google Scholar
• BASTOS M, MAEJI NJ, ABELES RH: Inhibitors of human heart chymase based on a peptide library. Proc. Natl. Acad. Sci. USA (1995) 92(15):6738–6742.
   Google Scholar
• •The research article describes peptidyl inhibitor design and optimisation through parallel synthesis.
   Google Scholar
• IIJIMA K, KATADA J, HAYASHI Y: Symmetrical anhydride-type serine protease inhibitors: structure-activity relationship studies of human chymase inhibi-tors. Bioorg. Med. Chem. Lett. (1999) 9 3) :413–418.
   PubMed Web of Science ®Google Scholar
• IIJIMA K, KATADA J, YASUDA E, UNO I, HAYASHI Y: Is1[2,2-Dimethyl-3-(N-(4-cyanobenzoyfiamino)nonan oyll-t-phenylalanine ethyl ester as a stable ester-type inhibitor of chymotrypsin-like serine proteases: structural requirements for potent inhibition of a-chymotrypsin. J. Merl. Chem. (1999) 42(2):312–323.
   Google Scholar
• EDWARDS PD, MEYER EF, JR., VIJAYALAKSHMI J et al.: Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl a-ketobenzox-azoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole. J. Am. Chem. Soc. (1992) 114 5) :1854–1863.
   Google Scholar
• •An early report in the development of a-ketoheterocycles as inhibitors of the serine protease elastase.
   Google Scholar
• HARPER JW, POWERS JC: Reaction of serine proteases with substituted 3-alkoxy-4-chloroisocoumarins and 3-alkoxy-7-amino-4-chloroisocoumarins: new reactive mechanism-based inhibitors. Biochemistry (1985) 24(25):7200–7213.
   Google Scholar